CLINDAMYCIN PHOSPHATE

Post-LOE

clindamycin phosphate topical

ANDATOPICALSWAB

Approved

Jun 2025

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

CLINDAMYCIN PHOSPHATE (clindamycin phosphate topical) is mechanism of action the mechanism of action of clindamycin in treating acne vulgaris is unknown. Approved for the treatment of acne vulgaris. First approved in 2025.

Drug data last refreshed 13h ago

Mechanism of Action

Mechanism of Action The mechanism of action of clindamycin in treating acne vulgaris is unknown.

Indications (1)

the treatment of acne vulgaris

Clinical Trials (4)

NCT07205107N/AActive Not Recruiting

Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris

Started Oct 2025

200 enrolled

Acne Vulgaris

NCT03122457Phase 2Completed

Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide

Started Jan 2017

22 enrolled

Actinic Keratosis

NCT01915732Phase 3Completed

A Efficacy and Safety of Duac™Compared With Clindamycin Phosphate Gel in the Treatment of Mild to Moderate Acne Vulgaris

Started Apr 2013

1,018 enrolled

Acne Vulgaris

NCT01915758Phase 1Completed

W0265-104: A Single-Center, Evaluator-Blinded, Randomized, Placebo-Controlled, Phase 1 Clinical Trial Evaluating the Photoallergic Potential of Topically Applied Clindamycin Phosphate 1.0% and Tretinoin 0.025% (CT Gel) in Healthy Volunteers

Started Nov 2008

64 enrolled

Acne Vulgaris

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.